U.S. Patient with Advanced NSCLC Achieves Disease Stabilization with Ivonescimab in China
核心洞察
A U.S. patient in his 70s with advanced non-small cell lung cancer and Parkinson's disease achieved disease stabilization using ivonescimab, a novel PD-1 (搜索)/VEGF (搜索) bispecific antibody available only in China.
The patient had exhausted all standard treatment options at MD Anderson Cancer Center before seeking treatment with ivonescimab at Jiahui International Cancer Center (搜索) in Shanghai.
Despite developing immune-related complications requiring ICU care, the patient's condition has stabilized with ongoing disease control management.
A U.S. patient with advanced non-small cell lung cancer (NSCLC) has achieved disease stabilization using ivonescimab, a novel immunotherapy currently available only in China, marking a significant milestone in international cancer care access.
The 70-something patient, who also has Parkinson's disease, had exhausted all standard lines of treatment at MD Anderson Cancer Center in the United States before his doctors recommended ivonescimab. The drug represents the first approved PD-1 (搜索)/VEGF (搜索) bispecific antibody for solid tumors.
Treatment Journey and Clinical Response
After a video consultation in late November scheduled within a week of their initial inquiry, the patient's family chose Jiahui International Cancer Center (搜索) (JICC) in Shanghai for treatment. The decision was based on the center's multidisciplinary expertise and leadership under U.S.-trained Medical Oncology Chief Dr. XUAN Linli.
During the course of treatment, the patient developed immune-related complications that required intensive care unit management. The cancer center rapidly coordinated a multidisciplinary response involving oncology, neurology, and critical care specialists, along with expert input from ivonescimab principal investigator Dr. Zhou Caicun.
The patient's condition has since stabilized, with ongoing care now focused on disease control. This outcome demonstrates the potential of ivonescimab in patients with advanced NSCLC who have failed multiple prior therapies.
International Treatment Access Model
As a tertiary international hospital partnered with Massachusetts General Hospital Cancer Center (搜索), Jiahui provides comprehensive international patient pathways, including remote consultations, travel coordination, and continuous family updates throughout treatment.
The patient's daughter expressed gratitude for the comprehensive care approach: "We are deeply grateful for the dedication, compassion, and tireless efforts of the entire Jiahui team: the doctors, nurses, kitchen and cleaning staff, the international team and front desk, and the care aides. My father would especially like to express his heartfelt thanks to Ms. Cui, who has cared for him every day since his admission. Beyond her attentive bedside care, she has offered him encouragement, comfort, and hope."
Global Impact and Future Implications
China's breakthrough oncology innovations are creating new treatment options for patients worldwide who have exhausted standard therapies in their home countries. JICC continues to receive growing inquiries and referrals from North America, Europe, Asia, and the Middle East, positioning Shanghai as an emerging global hub for advanced cancer care.
This case represents a notable shift in the global oncology landscape, where patients are increasingly seeking access to novel therapies approved in different regulatory jurisdictions. The successful management of this complex case, including the handling of immune-related adverse events, demonstrates the feasibility of international treatment seeking for breakthrough cancer therapies.